Patents Examined by Misook Yu
  • Patent number: 10794802
    Abstract: In various embodiments, the present application teaches methods for tissue clearing in which tissues are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches ePACT, which is a protocol for enhanced tissue clearing via expansion. In some embodiments, the present application teaches visualizing a tissue that has been expanded via ePACT.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: October 6, 2020
    Assignee: California Institute of Technology
    Inventors: Viviana Gradinaru, Jennifer Treweek
  • Patent number: 10654934
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: May 19, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • Patent number: 10537635
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: January 21, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
  • Patent number: 10386373
    Abstract: The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: August 20, 2019
    Assignee: Serimmune Inc.
    Inventors: Patrick Sean Daugherty, Kathryn Vinaya Louise Kamath, Jack Ryan Reifert
  • Patent number: 10336824
    Abstract: The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: July 2, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: James William West, Li Mei, Stephen James Moore, Margaret T. L. Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett
  • Patent number: 10316093
    Abstract: The present disclosure describes anti-B7H3 antibody agents and uses relating thereto. Among other things, the present disclosure demonstrates particular immunomodulatory effectiveness of certain such antibodies. The present disclosure further describes particularly high-affinity or otherwise useful antibodies and antibody agents based thereon, including particularly certain humanized and/or affinity matured versions of an 8H9 antibody. In some embodiments, provided antibody agents are useful, for example, in the treatment of cancer. In some embodiments, provided antibody agents are useful in relieving immunosuppression, for example mediated by B7H3-positive cells.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: June 11, 2019
    Inventors: Nai-Kong V. Cheung, Mahiuddin Ahmed, Qi Zhao
  • Patent number: 10227417
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 12, 2019
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Patent number: 10179820
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10111901
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa S H. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • Patent number: 10111900
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa Sh. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • Patent number: 10105310
    Abstract: The present invention relates to a composition comprising from 0.1 to 30% by weight of copolymer comprising polyether blocks and polyamide blocks (PEBA), and from 70 to 99.9% by weight of a medium which is acceptable in the cosmetics industry, in the perfumery industry and/or in the pharmaceutical industry. The present invention also relates in particular to a process for incorporating a copolymer comprising polyether blocks and polyamide blocks into a cosmetic, perfumery and/or pharmaceutical medium. The subject matter of the present invention is also the use of a copolymer comprising polyether blocks and polyamide blocks (PEBA) for producing a cosmetic, pharmaceutical or perfumery product, said PEBA being incorporated in the form of a composition in accordance with the invention.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: October 23, 2018
    Assignee: ARKEMA FRANCE
    Inventor: Frédéric Malet
  • Patent number: 10092567
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Patent number: 10064957
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 4, 2018
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 10030066
    Abstract: Disclosed is an immune receptor modifier conjugate, obtained from the reaction between a coupling precursor and a biotic ligand, the coupling precursor being a 9-position aminomethyl benzyl purine biotic coupling precursor, and the biotic ligand being selected from one or more of polypeptide, protein, glycoprotein, polysaccharide, polynucleotide, inactivated cells and inactivated microbes. The immune receptor modifier couplet can be used for immunomodulation, antibody preparation, anti-virus, diabetes, tumor immunomodulation, and tumor bio-immunotherapy. The conjugate compounds or salts thereof can be prepared into various therapeutic drugs, and can be prepared into a compound drug together with other drugs, or pharmaceutically acceptable carrier composites or conjugates. Also disclosed are compounds for synthesizing the coupling precursor and salts thereof.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: July 24, 2018
    Inventors: Guangyi Jin, Zhulin Wang
  • Patent number: 10010542
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 3, 2018
    Assignee: GB ACT, INC.
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Patent number: 10011657
    Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 3, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Han K. Kim, Louie Naumovski
  • Patent number: 9988462
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 5, 2018
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Patent number: 9982045
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 29, 2018
    Assignee: Novartis AG
    Inventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
  • Patent number: 9944708
    Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 17, 2018
    Assignee: BioNTech AG
    Inventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
  • Patent number: 9931412
    Abstract: Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: April 3, 2018
    Inventors: Sascha N. Goonewardena, Bertram Pitt, Hong Zong